NasdaqGS - Nasdaq Real Time Price • USD
Solid Biosciences Inc. (SLDB)
As of 12:48 PM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 8 | 8 | 7 | 7 |
| Avg. Estimate | -0.64 | -0.64 | -2.66 | -2.77 |
| Low Estimate | -1.09 | -1.13 | -3.73 | -3.76 |
| High Estimate | -0.52 | -0.39 | -2.03 | -1.8 |
| Year Ago EPS | -1.5 | -1.25 | -4.83 | -2.66 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 7 | 7 |
| Avg. Estimate | 1.21M | 1.21M | 4.14M | 4.67M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | 4.4M | 4.4M | 17.6M | 17.7M |
| Year Ago Sales | -- | -- | -- | 4.14M |
| Sales Growth (year/est) | -- | -- | -- | 12.80% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -2.05 | -1.53 | -1.19 | -0.99 |
| EPS Actual | -1.5 | -1.25 | -1.05 | -1 |
| Difference | 0.55 | 0.28 | 0.14 | -0.01 |
| Surprise % | 26.80% | 18.30% | 11.80% | -1.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.64 | -0.64 | -2.66 | -2.77 |
| 7 Days Ago | -0.64 | -0.64 | -2.66 | -2.77 |
| 30 Days Ago | -0.66 | -0.65 | -2.74 | -2.7 |
| 60 Days Ago | -0.99 | -1.02 | -3.34 | -2.54 |
| 90 Days Ago | -0.99 | -1.02 | -3.34 | -2.54 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | SLDB | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 57.30% | -- | -- | 1.50% |
| Next Qtr. | 48.80% | -- | -- | 11.40% |
| Current Year | 44.90% | -- | -- | 5.20% |
| Next Year | -4.10% | -- | -- | 13.40% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Initiated | William Blair: Outperform | 3/28/2024 |
| Maintains | Barclays: Overweight to Overweight | 3/18/2024 |
| Initiated | Citigroup: Buy | 3/15/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/14/2024 |
| Upgrade | Piper Sandler: Neutral to Overweight | 3/14/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/11/2024 |
Related Tickers
PEPG PepGen Inc.
11.39
-3.79%
ADCT ADC Therapeutics SA
4.5500
-4.81%
PTCT PTC Therapeutics, Inc.
25.15
-0.26%
SLRN Acelyrin, Inc.
4.3701
-4.37%
VYGR Voyager Therapeutics, Inc.
7.46
-1.52%
MTEM Molecular Templates, Inc.
1.5250
-6.91%
ZYME Zymeworks Inc.
8.19
-4.21%
QTTB Q32 Bio Inc.
26.93
+1.28%
SLNO Soleno Therapeutics, Inc.
38.02
-3.36%
WVE Wave Life Sciences Ltd.
4.7500
-5.19%